Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, and Oxurion today announced full enrollment of Oxurion’s Phase I trial designed to evaluate the safety of a single injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor. Activation of the PKal enzyme has been shown to induce retinal vascular permeability, microaneurysm and inflammation.
“Patients with DME have elevated levels of PKal,” said Patrik De Haes, M.D., Chief Executive Officer of Oxurion. “Our goal in this Phase I trial is to evaluate the safety of a single intravitreal injection of THR-149, a novel Bicycle-based PKal inhibitor, in subjects with visual impairment due to DME. Enrolling these patients is the first step to understanding whether we can inhibit PKal with Bicycle’s novel bicyclic peptides.”
Under the terms of the agreement, Oxurion (formerly ThromboGenics) has an exclusive license to undertake preclinical and clinical development, as well as subsequent commercialization, of a specified drug candidate. In return, Bicycle receives development milestone payments and royalties on sales of products resulting from the collaboration.
“Bicycles offer a differentiated approach to a range of debilitating diseases, and we are delighted to see the progress Oxurion has made in successfully completing the enrollment of the first Bicycle-based therapeutic for a Phase I study,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “THR-149, together with Bicycle’s own Bicycle Toxin Conjugate for oncology, BT1718, represent the first of multiple initiatives we are advancing to bring this unique therapeutic modality to patients with substantial unmet medical needs.”